Vertex Pharmaceuticals won FDA approval for its non-opioid painkiller Journavx. Vertex stock jumped in late trading.

Journavx is designed to eliminate the risks of addiction and overdose associated with medications like Vicodin and OxyContin.

Vertex Pharma has secured FDA approval for its non-opioid pain drug suzetrigine, becoming the first new class of pain ...

Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence ...

The drug offered more relief than a placebo in clinical trials, though it does not appear more effective than other pain ...

A new type of non-opioid painkiller, aimed at treating short-term pain in adults, has been approved by the US Food and Drug Administration (FDA). The drug suzetrigine, known by its brand name Journavx ...

Shares of Vertex Pharmaceuticals rose 8% in off-hours trading after the pharmaceutical company won U.S. approval for the [first new non-opioid painkiller in decades]( ...

Vertex Pharmaceuticals' newly FDA-approved non-opioid analgesic, Journavx, offers a groundbreaking alternative for managing ...

( The Hill) – The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first ...

The Food and Drug Administration on Tuesday approved Journavx, the first drug in a new class of non-opioid pain medications, ...

The new drug type targets pathways in the peripheral nervous system before pain signals reach the brain, potentially lowering ...